Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Neuronetics, Inc.NASDAQ: STIM
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 46.9%
Gross margin was 46.9% in Q1 FY2026, down 2.3 pp from a year earlier. On a trailing-twelve-month basis it was 48.0%, down 15.6 pp year over year. Over 3 fiscal years it narrowed by 27.8 pp.
Context
- Gross margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 48.5%
- Year-over-year change
- -23.8pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.5% | -23.8pp |
| FY2024 | 2024-12-31 | 72.3% | -0.1pp |
| FY2023 | 2023-12-31 | 72.5% | -3.8pp |
| FY2022 | 2022-12-31 | 76.3% | -2.7pp |
| FY2021 | 2021-12-31 | 78.9% | — |
Gross Margin vs competitors
How STIM compares with its peers on the latest reported figures
- STIM's LTM Mar 2026 gross margin of 48.0% is the 6th highest of the 10 companies compared; the peer median is 48.3%.
- Its year-over-year change of -15.6 pp is the 7th highest of 10, against a peer median of -0.1 pp.
- Over three fiscal years its change of -27.8 pp compares with a peer median of +0.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 100.0% | +0.0 pp | -8.3 pp | |
| LTM Mar 2026 | 83.9% | +12.4 pp | +14.2 pp | |
| LTM Mar 2026 | 71.1% | +4.4 pp | +25.6 pp | |
| LTM Mar 2026 | 58.3% | +12.7 pp | +25.3 pp | |
| LTM Mar 2026 | 48.3% | -17.2 pp | +0.4 pp | |
| LTM Mar 2026 | 48.0% | -15.6 pp | -27.8 pp | |
| LTM Mar 2026 | 41.0% | -1.5 pp | +3.6 pp | |
| LTM Mar 2026 | 35.5% | -64.5 pp | -118.2 pp | |
ATLNAtlantic International Corp. | LTM Dec 2025 | 10.6% | -0.1 pp | -1.7 pp |
| LTM Mar 2026 | -489.8% | -407.5 pp | -290.8 pp | |
| Peer median (excluding STIM) | 48.3% | -0.1 pp | +0.4 pp | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.31M | 65.21M | 71.35M | 74.89M | 149.16M |
| Cost of Revenue | 11.65M | 15.48M | 19.64M | 20.73M | 76.85M |
| Gross Profit | 43.66M | 49.72M | 51.71M | 54.16M | 72.31M |
| Gross Margin | 78.9% | 76.3% | 72.5% | 72.3% | 48.5% |
| Research & Development | 7.92M | 9.34M | 9.52M | 12.77M | 6.58M |
| Selling, General & Admin | 63.3M | 75.5M | 72.74M | 75.95M | 97.16M |
| Operating Expenses | 71.22M | 84.83M | 82.26M | 88.72M | 103.74M |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| EBITDA | (26.81M) | (31.96M) | (22.76M) | (34.37M) | (27.12M) |
| EBITDA Margin | -48.5% | -49.0% | -31.9% | -45.9% | -18.2% |
| Operating Income | (27.56M) | (35.11M) | (30.55M) | (34.56M) | (31.44M) |
| Operating Margin | -49.8% | -53.8% | -42.8% | -46.2% | -21.1% |
| Interest Income | 0 | 0 | 24K | 0 | 0 |
| Interest Expense | 3.3M | 3.6M | 5.42M | 7.29M | 8.42M |
| Other Income / Expenses | (3.61M) | (2.1M) | 365K | (9.18M) | (7.56M) |
| Income Before Tax | (31.17M) | (37.21M) | (30.19M) | (43.74M) | (39M) |
| Pre-Tax Margin | -56.4% | -57.1% | -42.3% | -58.4% | -26.1% |
| Income Tax Expense | 0 | 0 | (24K) | (14K) | 0 |
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.71M) | (39M) |
| Net Margin | -56.4% | -57.0% | -42.3% | -58.4% | -26.1% |
| EPS (Basic) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| EPS (Diluted) | (1.22) | (1.38) | (1.05) | (1.38) | (0.59) |
| Weighted Avg Shares | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M |
| Weighted Avg Shares (Diluted) | 25.48M | 26.9M | 28.66M | 31.73M | 65.95M |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.